Bladder cancer is the fourth most common cancer in men and one of the most significant causes of cancer-related death worldwide, with transitional cell carcinoma (TCC) being the predominant form (representing 90% of cases). 1,2 The superficial or nonmuscle-invasive TCCs, which could be managed by transurethral resection, tend to recur or progress. 3 The advanced or muscle-invasive TCCs are associated with a high risk of death from distant metastases. 4 Because of the lack of suitable diagnostic biomarkers and 
Introduction
Bladder cancer is the fourth most common cancer in men and one of the most significant causes of cancer-related death worldwide, with transitional cell carcinoma (TCC) being the predominant form (representing 90% of cases). 1, 2 The superficial or nonmuscle-invasive TCCs, which could be managed by transurethral resection, tend to recur or progress. 3 The advanced or muscle-invasive TCCs are associated with a high risk of death from distant metastases. 4 Because of the lack of suitable diagnostic biomarkers and effective therapies, patients are often diagnosed at advanced stages and the mortality rate keeps increasing. 5 Considering these issues, it is essential to study TCCs at the genetic level to characterize the targeted agents.
The improvement in high-throughput sequencing and big data mining with bioinformatics have provided enormous insights into the genomic landscape and identified new biomarkers in TCCs. 6 Sequencing of bladder cancer has identified recurrent mutations in TP53, FGFR3, TSC1, PIK3CA, RB1 and HRAS. 7 In recent years, our team have performed large-scale whole-genome and whole-exome sequencing of TCCs, which identified genetic alterations in the sister chromatid cohesion and segregation and chromatinremodeling processes as key hallmarks of TCCs. [8] [9] [10] Notwithstanding, the value of these emerging genes in TCC remains largely unknown, which merits further exploration and better understanding.
The gelsolin-like actin-capping protein CAPG (also known as macrophage-capping protein, AFCP, HEL-S-66, and MCP), is a calcium-sensitive actin-binding protein regulating cytoplasmic and nuclear structures. 11 The gelsolin protein superfamily is an evolutionarily conserved family of proteins present among species. As a member of the ubiquitous gelsolin family, CAPG is distinguished from other gelsolin proteins through unique features. 12 CAPG has only three repeated gelsolin-like domains, in contrast with the usual six domains, which probably leads to the lack of actin-severing activity of CAPG exhibited by the other family members. 11 The subcellular localization is another distinct feature of CAPG. It localizes to both the nucleus and cytoplasm, whereas the other gelsolin family members only present in the cytoplasm. 13 The nuclear section of CAPG is reported to be involved in phosphatidylinositoldriven chromatin remodeling 14, 15 and transcriptional regulation, 16 mainly through actin nucleation and assembly. 17 The cytoplasmic CAPG, on the other hand, caps the end of actin filaments in a Ca 2+ and phosphatidylinositol 4,5-bisphosphate-dependent (PIP2) manner. In addition, CAPG has been shown to regulate the actin cytoskeleton restructuring and cellular migrating in fibroblastic cells and endothelial cells. 18, 19 CAPG plays a crucial role in normal cells. More importantly, the deregulation of CAPG could result in cellular malignant changes. 20, 21 Through exploring the Cancer Genome Atlas (TCGA) data, we found frequent upregulation of CAPG in most cancers, especially in TCCs. However, the effects of CAPG in TCCs have not been illustrated to date. The current study set out to evaluate CAPG expression and its clinical significance and prognostic value. Secondly, we examined the biological effects of CAPG in malignant features of TCCs, both in vitro and in vivo. For this purpose, we selected nude mice (which harbor the genetic mutant resulting in a lack of body hair and an inhibited immune system) as a xenograft model in tumorigenesis experiments. While the SCID ('severe combined immune deficiency') mice, with neither mature B nor T-cells, are used for the tumor metastasis model. 22, 23 Thirdly, we explored the oncogenic mechanisms of CAPG in the development of TCCs. It is noteworthy that this study will further our understanding of TCCs as well as provide a potential therapeutic and prognostic target for this disease.
Materials and methods

Big data analysis
Illumina RNA Sequencing (version 2) transcriptome data and clinical characteristics of 413 cases with TCCs were retrieved from TCGA (http:// cancergenome.nih.gov/) and the cBioPortal (http://www.cbioportal.org) in January 2018. 24, 25 All provisional datasets were analyzed for CAPG expression, mutation, somatic copy-number alterations, clinicopathologic and survival analysis. The profile of CAPG was further analyzed in the Gene Set Enrichment Analysis (GSEA; 2.2.1, http://www.broadinstitute.org/gsea) to determine which pathway may be involved in CAPGmediated TCC progression. GSEA software of the present study used 'Hallmark gene sets [h.all. v5.2.symbols.gmt (Hallmarks)]' as the gene sets to be analyzed. We additionally searched for CAPG expression and copy-number variation in Oncomine (https://www.oncomine.org/resource/ login.html) across all available datasets (updated January 2018). 26 The immunohistochemistry (IHC) procedure and scoring of CAPG expression were performed as per the standard protocol. 27 Briefly, sections adhered to slides were deparaffinized with xylene and rehydrated prior to antigen retrieval by microwaving in sodium citrate buffer (pH 6.0). The sections were then incubated with primary antibody at 4℃ overnight. The antibodies used in IHC included CAPG (1:300 dilution, Sigma, MO, USA, HPA019080) and Ki67 (1:200 dilution, Abcam, CT, USA, ab15580). After washing with phosphate-buffered saline (PBS) three times, sections were incubated with a secondary antibody (1: 100 dilution, Santa Cruz, CA, USA) for 30 min at room temperature. The DAB substrate kit (DAKO, Carpinteria, CA, USA) was used for signal development, then they were counterstained by Mayer's hematoxylin, dehydrated, and mounted. Each slide was assessed by two pathologists independently. The score of CAPG expression was calculated as tumor cell staining multiplied by the score of staining intensity. The semiquantitative grading system was adopted as previously described. 28 Briefly, tumor cells staining was assigned a score using a six-category (0-5) grading system according to the percentage of stained tumor cell numbers. 16 ). All procedures were made to minimize the suffering and number of animals in compliance with the ethical standards of the institutional or national research committee. All animals used in this study were ordered from the Laboratory Animal Unit of the University of Hong Kong. All the mice were kept in standard cages at 26 ± 1°C under a 12/12 h light/dark cycle and fed the rodent standard diet with free access to water. The mice were randomly divided into control groups or experimental groups, with each group containing six mice.
Immunohistochemistry
For the in vivo tumorigenic study, we used 4-5-week-old male BALB/c nude mice (mean body weight: 15.5 ± 1.2 g), which were housed under standard conditions and cared for according to the institutional guidelines for animal care. 29 Control cells (SW780-Vec, 5637-shCtrl and T24-shCtrl) and CAPG-overexpressing or CAPG-knockdown cells (SW780-CAPG, 5637-shCAPG and T24-shCAPG) were subcutaneously injected into the right dorsal flank of nude mice in a laminar flow cabinet. The cell number injected into each mouse was 5 × 10 6 which were suspended in 150 µl PBS. The length (L) and width (W) of tumors were measured by calipers once every week and tumor volume was calculated by the formula V = 0.5 × L × W 2 . 30 After continuous observation for 6 weeks, mice were sacrificed, and tumors were excised, measured and collected for future pathological studies. For the mechanism study, in order to assess the effects of Yes-associated protein (YAP) inhibition in vivo, the nude mice were firstly subcutaneously injected with SW780-CAPG cells (5 × 10 6 / left flank and 1 × 10 7 /right flank). Then six mice were randomly chosen and injected with verteporfin (VP), the Hippo/YAP inhibitor (Sigma, 129497-78-5) once every other day starting from week 3 to week 5 in the dosage of 80 mg/kg intraperitoneally according to previous study. 31 The other six mice were treated with dimethyl sulfoxide (DMSO) in the same manner. After 6 weeks, mice were sacrificed, and tumors were removed, measured and collected for IHC staining to detect YAP (CST, #13008) expression.
For the metastatic model, we firstly infected SW780-CAPG and SW780-Vec cells with luciferase lentivirus. A total of 1×10 6 SW780-CAPGluciferase cells or SW780-Vec-luciferase cells were suspended in 100 µl sterile PBS and then injected into the tail vein of a 5-week old SCID mouse. A total of six mice were used for each group. Bioluminescent images were taken on the first day of injection and also every week after cell implantation to detect the tumor migration. After 5 weeks from the cell injection, mice were sacrificed, and the lungs were collected. The weight of the lungs and visible metastatic tumor nodules on the surface of the lungs were quantified.
CAPG overexpression and knockdown
The full-length wildtype CAPG cDNA (NM_001256139.1) was cloned (forward primer: 5' -ATGTACACAGCCATTCCCCA-3' and reverse primer:5'-TCATTTCCAGTCCTTG AAAAA TTGC-3') into the pCDH-cmv-mcs-EF1-Puro expression vector (Biosciences). Empty vector-transfected cells were used as controls (Vec). To inhibit CAPG expression efficiently, small interfering RNA specifically targeting CAPG was designed (sequences: 5′-TGATAT CTGATG ACTGCTT-3′) and transformed into short hairpin RNA (shCAPG). The sequence of scrambled shRNA (5′-TTCTCCGAACGTG TCACGT-3′) was used as negative control (shCtrl). To generate the lentivirus, vectors were inserted into the Lentivector Expression Systems (GeneChem, China) and then transfected into HEK 293T cells using Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer's instructions. After 72 h of incubation, the lentivirus particles were harvested from the transduced 293T cells, followed by the transfection to targeted TCC cells using polybrene (Sigma, USA). Stable clones were selected using puromycin (Sigma-Aldrich).
Quantitative real-time polymerase chain reaction Total RNA was extracted from the cells using the TRIzol reagent (Invitrogen) as per the manufacturer's procedures. The reverse transcription of cDNA was performed using a Reverse Transcription polymerase chain reaction (RT-PCR) kit (Roche). Quantitative RT-PCR was performed in triplicate using SYBR Green PCR kit (Applied Biosystems) and ABI PRISM 7900 Sequence Detector (Applied Biosystems). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression was used as an internal control. Primers were synthesized by Invitrogen (CAPG, 5′-GCAGCTCTGT ATAAGGTCTCTG-3′ and 5′-TTTCGCCCCT TCCAGATATAG-3′; GAPDH, 5′-TGACTTC AACAGCGACACCCA-3′ and 5′-CACCCTGT TGCTGTAGCCAAA-3′; forward and reverse). All results were expressed as fold changes in mRNA expression with respect to the control cells and the data were interpreted using the 2 −∆∆Ct method.
Western blot
Total protein was isolated from treated cells which were washed twice with PBS, harvested, and lysed with ice-cold protein lysis buffer [1 M Tris-HCl, pH = 6.8, 100 mM; 2% mercaptoethanol; 20% glycerin; 4% sodium dodecyl sulfate (SDS)]. Protein concentration level was measured using the BCA protein assay kit (Pierce, USA). Then the total 20 µg protein was loaded onto a gel electrophoresis SDS-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene difluoride membrane. The antibodies used for immunoblotting included CAPG (Sigma, HPA019080), GAPDH (CST, #5174), E-cadherin (CST, #3195), β-catenin (CST, #8480), vimentin (CST, #5741), N-cadherin (CST, #13116), Hippo signaling antibody sampler kit (CST, #8579) and the secondary antibody goat antimouse immunoglobulin (Ig)G horseradish peroxidase (HRP; Sigma-Aldrich, A4416) and goat anti-rabbit IgG HRP antibody (Sigma-Aldrich, A9169). Immunofluorescence Immunofluorescence (IF) staining was performed on TCC cells. Briefly, cells were seeded on coverslips at 50% confluence and fixed by 4% paraformaldehyde for 10 min and permeabilized in PBS with Tween (PBS-T; 0.05% Triton X-100) for 10 min. After blocking in 5% bovine serum albumin for 30 min at room temperature, the cells were incubated with primary antibodies at 4°C overnight. After washing three times in PBS, cells underwent incubation with secondary antibodies in a dark humidified chamber for 1 h at room temperature. The nucleus was stained by 4',6-diamidino-2-phenylindole (DAPI; Invitrogen, CA, USA). The images were visualized under Carl Zeiss LSM700 fluorescence microscope (Zeiss, Germany) and analyzed using ImageJ software (National Institutes of Health, Bethesda, MD, USA).
Cell proliferation assays
An XTT assay (Roche Applied Science, Germany), Celigo Imaging cell cytometer (Nexcelom, USA) and foci formation assay (Sigma-Aldrich) were used according to the manufacturer's instructions. For a standard vitality XTT assay, each cell line was cultured in 96-well plates at a density of 2 × 10 3 cells per well. After adding XTT reagent (20 μl per well, 5 mg/ml), cells were incubated at 37°C for 2 h. The cell growth rate was then measured by detecting the absorbance value through a spectrophotometer (Tecan Sunrise, Switzerland) using a measure wavelength of 490 nm. Cell viability was monitored daily for total 5 days. Overall, three independent experiments were performed and each was done in triplicate. Another cell proliferation test was examined by using the Celigo Imaging cell cytometer. TCC cells were plated at 2000 cells/well in 96-well plates in the complete medium at 37°C with 5% CO 2 in air on day 1. The number of cells in each well was counted daily from day 2 to day 5. The proliferation rate was expressed as a ratio of the cell counts on days 2-5 normalized against day 1. For the foci formation assay, 1-3 × 10 3 cells were plated in each well of a six-well plate. After 7-10 days culture, surviving colonies were fixed with 100% ethanol and counted with crystal violet staining. Overall, three independent experiments were performed. The foci numbers were calculated by ImageJ software (National Institutes of Health).
Cell apoptosis assays
To detect cell apoptosis, Annexin V-APC apoptosis detection kit (eBioscience, USA) was used following the manufacturer's protocol. After treatment, cells were re-suspended at a concentration of 1 × 10 6 /ml in 200 μl binding buffer (1×). Then 5 μl Annexin V-APC was added to each 100 μl cell suspension. The cells were mixed and incubated at room temperature for 15 min and then analyzed by flow cytometry (FACS; Millipore, Guava easyCyte HT). The experiment was performed three times. Apoptotic cells were also detected using Caspase-Glo 3/7 assay kit (Promega, USA). Briefly, cells were re-suspended in 100 μl of culture medium and mixed with 100 μl of caspase substrate. Lysates of cells were diluted to a concentration of 1 × 10 4 cells/well and incubated for 4 h at room temperature. The fluorescence was measured with an excitation wavelength of 485 nm and an emission wavelength of 530 nm under the fluorescence microscope (Olympus, IX71).
Cell migration and invasion assays
A wound-healing assay was used to determine the cell mobility. Briefly, cells were cultured in a sixwell plate. The culture medium was replaced by serum-free medium 24 h before a wound scratch. After wounding by a sterile tip, the medium was changed to remove cellular debris. Serial photographs were taken at different time points. In addition, migration and invasion assays were conducted in the 24-well Transwell Chambers (Corning, USA) or the Matrigel BioCoat Invasion Chambers (Corning, USA). Briefly, cells were seeded into the upper chambers at the density of 1 × 10 5 cells per well and cultured in 500 μl serum-free medium at 37°C for 1 h. Then 700 μl medium containing 30% FBS was added to the lower chamber and then incubated at 37°C for 24 h or 48 h. Cells transmigrating the membrane or invading through Matrigel were fixed, stained with crystal violet and counted using an inverted phase contrast microscope and photographed (Cikong, XDS-100).
Microarray procedure
The quality of total RNA samples was assessed by Nanodrop 2000 (Thermo Scientific, MA, USA) and Aglient 2100 Bioanalyzer (Agilent Technologies, CA, USA). Total RNA was isolated 48 h after transfection and analyzed by using 6 journals.sagepub.com/home/tam the GeneChip Primeview Human Gene Expression Arrays (Affymetrix, USA). Briefly, the Affymetrix GeneChip 3'IVT Express kit was used for cDNA target preparation. The fragmented and labeled cDNA was generated and hybridized onto Human Gene 1.0 ST arrays in Affymetrix GeneChip Hybridization Oven 645. Arrays were washed, stained and processed using Affymetrix GeneChip Fluidics Station 450 systems. Then they were imaged using an Affymetrix GeneChip Scanner 3000 for the subsequent generation of raw data.
Ingenuity Pathway Analyses
Ingenuity Pathway Analyses (IPA) software (Qiagen, USA) was performed to reveal the canonical pathways, upstream transcriptional regulators, biological processes and molecular networks following CAPG upregulation. The list of differentially expressed genes, containing gene identifiers and corresponding expression values, was uploaded into IPA. Every gene identifier was mapped to its corresponding gene object in the Ingenuity Pathway Knowledge Base (IPKB). Canonical pathway analysis was used to identify networks from the IPA library that were most significantly modulated across anatomical sites. Functional enrichment analysis identified the biological functions or diseases that were most significant to the data set. The likeliness that a group of the candidate genes is involved in a represented function is measured by the significance value. The significance of the association between each data set and specific pathways or functions, was determined in three ways: (1) A p value calculated by Fisher's exact test to determine the probability of the association between genes in the dataset and the pathway of interest; (2) A z-score inferring the overall activation or inhibition states of functions caused by transcriptional regulators; and (3) a ratio calculated by the molecule's number from the dataset mapped to the pathway versus the total molecules' number mapped to the IPKB pathway. proportional hazard regression models were used to examine independent prognostic predictor variables. A Student's t test was applied to assess the statistical significance between two preselected groups. The one-way analysis of variance (ANOVA) was used to determine the significant differences between two or more independent groups. The data are presented as the mean ± standard deviation (SD) of three independent experiments. The p values are denoted as *p < 0.05, **p < 0.01, ***p < 0.001 in all figures.
Statistical analysis
Results
CAPG is frequently upregulated in TCCs and correlated with poor prognosis
We systematically analyzed CAPG mRNA expression in 20 cancer types using the latest RNA sequencing dataset from TCGA and identified that CAPG was significantly upregulated in 13 cancer types, for example, thyroid cancer, breast cancer (BRCA) and bladder cancer (BLCA) as shown in Figure 1 Upregulation is a common feature of oncogenes, which can be caused by mutation, gene amplification, and translocation. 32 We further examined CAPG gene alterations in TCGA datasets using cBioPortal. Notably, among all cancer types with TCGA data, the CAPG gene was most frequently amplified in TCCs [BLCA; Supplementary Figure  1 The tumorigenic potential of CAPG was assessed by cell proliferation assays including XTT assay, foci formation assay, Celigo assay and xenograft tumor formation study (Figures 2 and 3) . With respect to the control group, the cellular proliferative rate of SW780-CAPG cells were remarkably enhanced in XTT assay [ Figure 2 Hence, these data demonstrated that CAPG has a strong tumorigenic ability both in vitro and in vivo.
CAPG could also inhibit apoptosis in TCC cells. We observed a significant decrease in the number of apoptotic cells using flow cytometry assays after overexpression of CAPG in SW780 cells compared with the control. The caspase 3/7 activity was also downregulated by CAPG upregulation [ Figure 2 (f and g)]. Conversely, as shown in Figure 3 (e) and (f), the apoptosis rates of the T24 and 5637 cells in shCAPG groups were significantly higher than the negative control group. The caspase 3/7 activity were upregulated in T24 and 5637 cell lines treated with shCAPG lentivirus compared with the shCtrl group.
CAPG promoted TCCs metastasis as an EMTinducing factor
Several studies have showed that CAPG is involved in the control of actin-based cell motility of benign cells and malignant cells. 20, 21 Furthermore, the analysis of big data and TCC clinical specimen indicated that overexpression of CAPG was associated with lymph node metastasis and tumor stage progression. These evidences raise the possibility that CAPG also plays an important role in facilitating TCCs metastasis. Therefore, we investigated whether CAPG could promote migration and invasion capacity in TCC cells. After establishing the stable CAPG-upregulated SW780 cells and CAPG-downregulated 5637 cells as previously described, a CAPG plasmid was transfected to the CAPG-downregulated 5637 cells to re-overexpress the CAPG gene and the shRNA plasmid was transfected to the CAPG-upregulated SW780 cells to re-knockdown the CAPG gene. The CAPG expression in mRNA and protein levels are shown [ Figure 4 (a i and ii)]. In the wound-healing assays, the CAPG gene expression was increased by 519 % and enhanced the migration rate by 174% in the SW780-CAPG group compared with the SW780-Vec group, while the CAPG level fell by 218% and exhibited a decrease in the migration rate of 88% in the SW780-CAPG-shCAPG group compared with SW780-CAPG group [ Figure 4 The Hippo pathway is involved in a wide range of biological processes, such as organ size control, cell differentiation, tumorigenesis and cancer development. 33, 34 To read out the status of the Hippo pathway regulated by CAPG in TCCs, we firstly examined the expression of the core components of Hippo using a western blot, including the cytosolic kinases: the mammalian Hippo homolog1 (MST1) and large tumor suppressor 1 However, the phosphorylation of MST1 and SAV1 were not significantly changed by the regulation of CAPG. The phosphorylation of YAP causes the cytoplasmic sequestration of YAP, which could prevent its nuclear translocation and function as a transcriptional coactivator. 35, 36 We therefore detected the subcellular distribution of YAP by immunofluorescence staining. CAPGoverexpressing SW780 cells had decreased levels of cytoplasmic YAP and increased levels of nuclear YAP. Conversely, knockdown of CAPG in 5637 cells reduced the nuclear localization of YAP [ Figure 5 (f)]. These results suggested that downregulated CAPG triggered a kinase cascade leading to phosphorylation, cytoplasmic retention and functional inactivation of YAP and vice versa.
To further delineate the key role of Hippo signaling in the tumorigenesis and metastasis regulated by CAPG, the function of Hippo was suppressed by a YAP inhibitor, VP, a compound being reported to induce sequestration of YAP in cytoplasm and interfere with YAP transcription binding effectively. VP was dissolved in DMSO (100 mg/ml), and a working solution was freshly prepared at 10 mg/ml in PBS before use. In vitro, CAPG-overexpressed SW780 cells were treated with VP at 1 μM/ml or 3 μM/ml and blank control (DMSO) for 24 h. The cellular location of YAP was then determined by immunofluorescence staining. As indicated in Figure 6 (a), VP decreased YAP nuclear localization leading to increases in cytosolic YAP in a dose-dependent manner.
XTT assay and foci formation assay demonstrated that VP decreased the SW780-CAPG cells proliferation in vitro. Consistently, the inhibition of YAP abrogated the effects of CAPG on migration and invasion abilities in SW780 cells [ Figure 6 Taken together, these findings suggest that the tumorigenesis and metastasis caused by CAPG is associated with the Hippo pathway in TCCs ( Figure 7 ).
Discussion
TCC is highly prevalent worldwide. It is characterized by frequent recurrence and high mortality. Unfortunately, our understanding of the genetic basis of TCC is limited, which is reflected by the absence of effective treatment modalities and prognostic markers. 37 Thus, appropriate molecular biomarkers for TCCs are needed urgently. In many other areas, actin-regulating proteins are being proposed as potential targets for drug development at a swift pace. 38 As a member of gelsolin-family, CAPG exerts important biological and physiological functions in various tissues. However, the functional characterization of CAPG in TCCs has not been studied.
Based on our findings, CAPG was highly activated in a wide variety of cancers, especially in TCCs. And the upregulation of CAPG was found to be associated with the gene copy-number amplification. Though the oncogenic function of CAPG has been reported in different cancers by investigators, 20, 21, [39] [40] [41] [42] the relationship between activation of CAPG and the development of TCCs is still unknown to the best of our knowledge. In the present study, we showed for the first time the frequently upregulation of CAPG detected in clinical specimens of primary TCCs, which was significantly associated with lymph node metastasis (p = 0.0077), advanced pathologic stage (p = 0.0003) and worse prognosis (p = 0.0080). Thus, CAPG could be an independent prognostic factor in patients with TCCs.
The data presented here also revealed the previously undescribed findings that upregulation of CAPG led to tumorigenesis of TCCs and enhanced metastasis and EMT in TCC cells. Lymph node metastasis is the first step and the most typical pattern in the metastatic process in TCCs. 43 As a prerequisite for tumor cell invasion and metastasis, cellular mobility could be mediated by CAPG in normal cells as well as cancer cells. With the lack of cytoplasmic CAPG protein, cells fail to reorganize their actin cytoskeleton properly during motility, probably through inappropriate elongation of actin filaments. Though Sarah Tonack and colleagues suggested that the cytoplasmic CAPG may be sufficient for increased cell motility, 44 the specific ability of CAPG to enter the nucleus might also trigger the invasion . 45 The mechanism of CAPG improving cellular motility remains controversial.
EMT was shown to strongly improve cellular motility and dissemination in cancers, including TCCs. 46 It has been reported that during EMT process, activation of RhoA leads to actin cytoskeleton remodeling and disruption of E-cadherin based cell adhesions. 47 Several actin cytoskeleton-associated proteins such as α-actinin, integrins and moesin have been shown to be positively related to EMT. 48 We therefore wondered whether the cytoskeleton modulation protein CAPG could regulate EMT in TCCs. GSEA analysis on the basis of RNA-seq data from TCGA indicated that EMT signaling was significantly enriched in the CAPG-overexpression group. We next validated that the overexpression of CAPG could downregulate epithelial markers expression while upregulating the mesenchymal markers. Thus, CAPG could contribute to motility not only by cytoskeleton restructuring but also through EMT in TCC cells, which further our understanding in this regard. In an attempt to investigate the molecular mechanisms underlying CAPG regulating tumorigenesis, a recent study reported that CAPG promoted tumorigenesis due to changes of the tumorrelated proteins such as STAT4, ANK3 and IGF2. 49 Sheng Huang and colleagues reported that CAPG enhances BRCA metastasis by competing with PRMT5 to modulate STC-1 transcription. 50 Notably, in the current study, we uncovered a novel mechanism of CAPG inactivating the tumor suppressive pathway Hippo, then leading to the nuclear translocation of the oncogene YAP in TCCs. Hippo signaling is a highly conserved developmental pathway that plays an essential role in restricting organ size, tumor suppression, tissue regeneration and stem cell self-renewal. 51 The core of the Hippo pathway is a kinase cascade consisting of MST1/2 and LATS1/2. The MST1/2 kinases combined with SAV1 to activate the LATS1/2 kinases. 52 Activated MOB1-bound LATS1/2 phosphorylates YAP on serine residues, to block its nuclear import and results in inhibition of its transcriptional programs. 36 On the other hand, when the Hippo pathway is inactive, unphosphorylated YAP could translocate to the nucleus where it binds to TEA Domain Transcription Factor (TEAD) transcription factors and activate oncogenic genes. It has been reported that Hippo signaling was inactivated in human breast, prostate and colon cancer cell lines. 53 However, upstream signals that regulate the Hippo pathway are largely unknown. It has been shown that a variety of manipulations affecting the F-actin cytoskeleton can modulate the Hippo pathway. 54, 55 Zhao and colleagues advanced the evidence that cell detachment and the microtubule cytoskeleton play important roles in stimulating LATS1/2 kinase activity and YAP phosphorylation. 56 Our findings suggested that CAPG overexpression inactivated the Hippo signaling through LATS1 and MOB1 dephosphorylation. Given that CAPG could regulate F-actin and the cytoskeleton, whether CAPG inactivates Hippo signaling through F-actin or other factors needs further exploration.
Conclusion
In conclusion, our data suggested a critical role for CAPG as an oncogene in TCCs and a positive relationship between CAPG and the clinical aggressiveness of patients with TCCs, which implicated the potential of CAPG as a prospective prognostic biomarker for TCCs. We further validated that the Hippo pathway had a crucial role in CAPG-mediated TCC development. The current results, together with previously reported evidence, pave the way for novel tumor diagnosis and treatment strategies with CAPG as a target for decreasing the malignant properties of TCCs.
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